Gilead Expands Access to Investigational Obeldesivir for Ebola Bundibugyo Virus Disease Through Voluntary Licensing
Can Gilead Sciences' HIV Business Fuel Sustainable Long-Term Growth?
Gilead Brings HIV Prevention to the 27th Annual Latin GRAMMY Awards®
Gilead (GILD) Stock Still Looks Undervalued On Its 205% Run
Gilead Sciences (GILD) Posts PURPOSE 5 Win As HIV Shot Beats Daily Pills
Gilead Sciences (GILD) After Trial Wins And Raised Guidance Looks Fully Valued
Gilead Sciences Targets 200 Treatment Centers for Potential Anito-Cel Launch
Gilead Sciences, Inc. (GILD) Presents at 8th Annual Wolfe Research Healthcare Conference Transcript
Gilead Highlights Strong Trial Results in HIV Prevention and Liver Disease
Gilead Pays a $3.28 Annual Dividend Despite Negative Earnings. Is It Safe?
Here's How Much $1000 Invested In Gilead Sciences 20 Years Ago Would Be Worth Today
New Data Show Twice-Yearly Lenacapavir Achieved Nearly Twice the One-Year Persistence of Daily Oral F/TDF in HIV Prevention
Gilead’s Twice-Yearly HIV Prevention Injection Shows 85.6% Persistence And Zero HIV Acquisitions in 52-Week Trial
Gilead seeks wider use for Livdelzi on Phase III liver disease success
Positive Phase 3 IDEAL Study Results Further Support Livdelzi®’s (Seladelpar) Impact on Achieving ALP Normalization Goals in Second-Line Treatment Across a Broad Population of People Living with Primary Biliary Cholangitis (PBC)
Did Earnings Beat Just Shift Gilead Sciences' (GILD) Investment Narrative?
Gilead Sciences Reports Phase 3 IDEAL Success For Livdelzi In PBC, With 75.4% Achieving ALP Normalization At Week 52 Vs 16.1% Placebo; Serious Adverse Events 3.1% Livdelzi Vs 12.9% Placebo; None Related To Drug
Gilead Sciences Has Raised Its Dividend for 11 Straight Years. Here's Why the Streak Looks Safe.
Gilead and Kite Advance Leadership With New Data Across Pipeline and Portfolio at ASH 2026
Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.